New Daily Persistent Headache (NDPH)NDPHNCT05984719
New Daily Persistent Headache Survey
An observational study of New Daily Persistent Headache (NDPH) and New Daily Persistent Headache, run by The University of Texas Health Science Center, Houston at 1 site in United States.
Trial summary
Purpose: to explore headache characteristics and treatment effects of patient with new daily persistent headache (NDPH) through an online survey. Research design: Online survey of patients with new daily persistent headache. Read more about this study
- Who is it for?
- Ages 13 years and older
- Conditions the study is for
- New Daily Persistent Headache (NDPH), New Daily Persistent Headache
- How many people
- 803 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Jun 2023to 31 Jan 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The population is participants with a diagnosis of NDPH. The NDPH diagnosis must come from a physician and will be further assessed with disease-specific survey questions.
Who may be able to join
- Patients with NDPH that have been diagnosed by a health care professional (no documentation is needed, participant must simply state that he or she has been diagnosed)
Who cannot join
- Unable to speak English (the survey is only in English)
- Unable to use a computer to take the online survey
Trial locations and contacts
1 site in 1 country.
About this study
Official title: New Daily Persistent Headache Patient Experience Survey
Purpose: to explore headache characteristics and treatment effects of patient with new daily persistent headache (NDPH) through an online survey.
Research design: Online survey of patients with new daily persistent headache.
Risks: Risks include a breach of confidentiality as well as fatigue from taking the survey online.
Importance of knowledge that may recently be expected to result: The study aims to discover new information in a very understudied disease. This information could, in future studies, help change the diagnostic criteria or lead to new treatment options.
- Keywords
- Constant headache, Refractory headache disorder
- Medical subject headings
- Headache Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| New daily persistent headache (NDPH) group | Participants with NDPH will be administered an online survey. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Survey data
Measured: At study completion, expected to be in 6-12 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2023
- Study start19 Jun 2023
- Primary completion31 Jan 2024
- Study completion31 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for New Daily Persistent Headache (NDPH)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 803 participants (actual)
Sponsor and investigators
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mark J Burish, The University of Texas Health Science Center, Houston
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05984719
- Sponsor's protocol ID
- HSC-MS-23-0206
- Acronym
- NDPH
- Status last verified
- Feb 2026
- First submitted
- 30 Jul 2023
- Last updated
- 18 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- New Daily Persistent Headache Patient Experience Survey
- ClinicalTrials.gov ID
- NCT05984719
- Acronym / sponsor ID
- NDPH / HSC-MS-23-0206
- Keywords
- Constant headache, Refractory headache disorder
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 803 participants (actual)
- Lead sponsor
- The University of Texas Health Science Center, HoustonUniversity, hospital or other
- Study start
- 19 Jun 2023 (actual)
- Primary completion
- 31 Jan 2024 (actual)
- Study completion
- 31 Jan 2024 (actual)
- First posted
- 9 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Purpose: to explore headache characteristics and treatment effects of patient with new daily persistent headache (NDPH) through an online survey.
Research design: Online survey of patients with new daily persistent headache.
Risks: Risks include a breach of confidentiality as well as fatigue from taking the survey online.
Importance of knowledge that may recently be expected to result: The study aims to discover new information in a very understudied disease. This information could, in future studies, help change the diagnostic criteria or lead to new treatment options.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| New daily persistent headache (NDPH) group | – | –Participants with NDPH will be administered an online survey. |
Who may qualify
- Ages
- 13 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The population is participants with a diagnosis of NDPH. The NDPH diagnosis must come from a physician and will be further assessed with disease-specific survey questions.
Key inclusion criteria (1 listed)
- Patients with NDPH that have been diagnosed by a health care professional (no documentation is needed, participant must simply state that he or she has been diagnosed)
Key exclusion criteria (2 listed)
- Unable to speak English (the survey is only in English)
- Unable to use a computer to take the online survey
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Survey data
Time frame: At study completion, expected to be in 6-12 months.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2026.
- Link to the online survey - participants can go here directly. (For more information first, call the study team at 713.486.7771 or email the study team at nctt.wec@uth.tmc.edu)Link provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for New Daily Persistent Headache (NDPH)
RecruitingObservational study
China HeadAche DIsorders RegiStry
Headache Disorders, Primary, Migraine
RecruitingObservational study
Analysis of Headache Chronification With Imaging, Deep Phenotyping, and Proteomics
Chronic Daily Headache, Chronic Migraine
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of New Daily Persistent Headache (NDPH) and New Daily Persistent Headache, run by The University of Texas Health Science Center, Houston at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Survey data (time frame: At study completion, expected to be in 6-12 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.